DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN’S DISEASE IN SUSTAINED, COMBINED CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL

Sine Buhl  ¹     Casper Steenholdt  ¹     Jørn Brynskov  ¹     Katrine Risager Christensen  ¹     Maria Dorn-Rasmussen  ¹     Ole Østergaard Thomsen  ¹     Klaus Bendtzen  ¹     Tobias Wirenfeldt Klausen  ¹     Jens Frederik Dahlerup  ²     Niels Thorsgaard  ³     Jørgen Jahnsen  ⁴     akbar molazahi  ⁵     Natalia Pedersen  ⁶     jens kjeldsen  ⁷     Sven Almer  ⁸     Eva Efsen Dahl  ⁹     Ida Vind  ¹⁰     Annett Cannon  ¹¹     Jan Marsal  ¹²     Taina Sipponen  ¹³     Jørgen Agnholt  ¹³     Hendrika Adriana Linda Kievit  ¹³     Synnøve Louise Aure  ¹³     Lars Martin Martinsen  ¹⁴     Svetlana Meisner  ¹⁴     Jane Møller Hansen  ¹⁴     Mark Andrew Ainsworth  ^14    
1 Copenhagen University Hospital at Herlev, Herlev, Denmark
² Aarhus University Hospital, Aarhus, Denmark
³ Herning Regional Hospital, Herning, Denmark
⁴ Akershus University Hospital, Lørenskog, Norway
⁵ Nykøbing Falster Hospital, Nykøbing F, Denmark
⁶ Slagelse Hospital, Slagelse, Denmark
⁷ Odense University Hospital, Odense, Denmark
⁸ Karolinska University Hospital, Stockholm, Sweden
⁹ Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark
¹⁰ Hvidovre Hospital, Hvidovre, Denmark
¹¹ Silkeborg Regional Hospital, Silkeborg, Denmark
¹² Skånes Universitetssjukhus, Lund, Sweden
¹³ Helsinki University Hospital, Helsinki, Finland
¹⁴ Thisted Hospital, Thisted, Denmark

Topic
IBD, Immunology

Session
IBD: Clinical trials IV

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)